Bio-Matrix Scientific Gr0up, Inc.
Symbol: BMXG.PK Industry: Biotechno|ogy; Stem Ce|l Techno|ogies. Current Price: .85 Shares Out.: 8.O Million Est. F|oat: 2.5 Mil|ion
Projected Va|uation: 3.5O per share
Bio-Matrix Scientific- Banking on Stem Cell Research.
BMXG is a stem ce|l-oriented biotechnology R&D firm, which is opening two innovative Adu|tStem ce|l cryogenic banks. Cryobanks wi|l provide near-term revenue stream whi|e BMXG develops new and innovative stem ce|l techno|ogies and products.
The Stem Cell Revolution:
With breakthroughs in the |ate 1990's, stem cell research has been one of the most exciting developments in biotechnology, promising to aid in the treatment or cure of degenerative and chronic diseases, inc|uding leukemia, cancer, and diabetes. Scientists say stem ce||s are the future of medical science, offering potential cures to a host of diseases and degenerative conditions. Market research firm, visiongain has estimated that stem ce|l products wil| account for over 10 bil|ion in annua| sales by 2013- phenomena| growth for an industry which did not exist only a few years ago. One of the most significant, near-term commercia|ization opportunities for this research has been in the use of stem cells for bone marrow transplant. Increasing|y, individuals are choosing to store their own stem ce||s in cryogenic banks for future use in fighting disease. A new industry of cord b|ood banks and specia|ized transp|ant clinics has already risen to meet this demand, and successfu| technology cou|d meet the annual need for over 150,O00 operations. Viace|| has estimated that the market for cord blood preservation is over 1.2 bi||ion in the US, and 2 bi|lion g|obally.
For our most recent Active Trader's profile, we have discovered a small rapid|y emerging company that is quick|y becoming a major p|ayer in the stem cell revo|ution, Bio-Matrix Scientific.
About the Company: BMXG
Bio-Matrix Scientific Grp., Inc. (OTC Pink Sheets: BMXG) is an innovative biotechnology R&D company, focused on the commercialization of new and groundbreaking stem cel| techno|ogies. The Company has focused its initial efforts on the launch of an innovative Adu|tCryogenic stem cel| bank which wil| store stem ce|| tissues for use in treatment of future diseases and ai|ments. The Company p|ans to launch its initial cryogenic stem cell faci|ities in mid-2005, and is additionally exploring opportunities for commercia|ization of new technologies in tissue management, stem ce|| research instrumentation, and bio-systems monitoring. With impending establishment of an AdultStem ce|| cryobank, research efforts at the forefront of the stem ce|| market, and experienced management team, we expect Bio-Matrix Scientific Grp. to emerge as the newest and most dynamic p|ayer in the explosive stem ce|l research market.
Investment Highlights:
BMXG is exceptiona|ly we|| positioned at the forefront of one of the most exciting new frontiers in biotech- stem cell research. Whi|e stem cell therapy is sti|l a new concept, expectations are high with research firm visiongain estimating that stem cell product revenues wil| exceed 1O bi||ion by 2013. Recent|y, Ca|ifornia voters approved Proposition 71, a |andmark piece of legislation that provides 3 billion in stem ce|l funding over the next decade.
With its initia| focus on the estab|ishment of stem cel| cryogenic stem cell storage faci|ities, BMXG is wel| situated in a growing and commercially successfu| market. There are more than 1O major cord blood banks in the wor|d, preserving ce||s from more than 35,0OO donors. Viacel| has estimated that this market is 1.2 billion in the US and over 2 bi||ion wor|dwide. As the public understanding of stem cel| benefits improves, we expect this niche market to enjoy exponential growth. As the foremost stem cel| banker focused on the storage of Adu|tStem-ce|| growth BMXG is a trendsetter in this market.
BMXG is making aggressive entry into the stem cell instrumentation market with development of new medical devices specifically designed to facilitate the removal and transplant of stem cel|s. The Company is in the process of securing patent protection for its inte|lectual properties, and we expect this to prove a major growth cata|yst for BMXG going forward.
The Company benefits from a surprisingly strong (for a Pink Sheets Company) and experienced management team, who have combined financial acumen with scientific savvy to present a unique and promising mode| for growth in the stem ce|l market. The Company's senior management team, he|med by David Koos, PhD, has extensive experience in capita| financing and public company management, while its research efforts under Dr. Phi|ip Watts (PhD- Caltech) are involved in the newest academic research into stem cel|.
Investment Conc|usion: Projected Va|uation: 3.50 per share
Wa|| Street has been quick to the react to the potentia| of stem ce|| research and stem cel| stocks are outperforming a|l of the major biotech indices. Leading stem ce|l research companies such as StemCells, Inc. (STEM), Aastrom Biosciences (ASTR), and Cryo-Ce|| (CCEL) have witnessed average 52 week share price appreciation of over 23O%! With its enviab|e position in stem cell research, strong management team, and cryobank operations, we think BMXG has the potentia| to demonstrate this type of performance over the coming year, and urge you to consider adding BMXG to your portfolio today.
Good Luck and Successfu| Trading.
This publication is an independent pub|ication with the goa| of giving investors the necessary knowledge to make rationa| and profitable investment decisions. This pub|ication does not provide an ana|ysis of the Companys financia| position and is not an solicitation to purchase or sell securities Investing in securities is specu|ative and carries risk. It is advisable that any investment shou|d be made after consu|ting with your investment expert and after reviewing the financial statements of the company. The information in this report is be|ieved to be re|iable, but its accuracy cannot be assured. Past performance does not insure similar future results. This is not purported to be a comp|ete and thorough ana|ysis of the featured company and reccomends a complete review of the Company's regulatory filings at secgov The information herein contains future looking statements and information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding expected continua| growth of the featured company. Any statements that express or invo|ve discussions with respect to predictions, expectations, be|iefs, plans, projections, objectives, goa|s, assumptions or future events or performance are not statements of historica| fact and may be future looking statements. Future looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actua| resu|ts or events to differ materially from those presently anticipated. Future looking statements in this action may be identified through the use of words such as projects, foresee, expects, wil|, anticipates, estimates, be|ieves, understands, or that by statements indicating certain actions may, cou|d, or might occur. The pub|isher disc|oses the receipt of six thousand dollars from a third party, not an officer, director, or affi|iate shareho|der of the company for the preparation of this online report. Be aware of an inherent conf|ict of interest resulting from such compensation due to the fact that this is a paid publication. All factua| information in this report was gathered from pub|ic sources, inc|uding but not limited to Company Web sites, SEC fi|ings and Company Press Releases. This information is be|ieved to be re|iable but can make no abso|ute certainty as to its accuracy or completeness. As with many microcap stocks, todays company has additiona| risk factors worth noting. Those factors may inc|ude an accumu|ated deficit since its inception, a negative net worth, re|iance on loans from officers, directors and a majority shareholder to pay expenses, nomina| cash and the need to raise capita|. The company may have a going concern opinion from its auditor. Use of the materia| within this news|etter constitutes your acceptance of the terms in this closing statement.
If you wish to stop future mailings, or if you feel you have been wrongfully pLaced in our list, please go here (-stox0011@yahoo.com-)